GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EV-to-EBIT

BCAL Diagnostics (ASX:BDX) EV-to-EBIT : -2.78 (As of May. 25, 2025)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, BCAL Diagnostics's Enterprise Value is A$22.11 Mil. BCAL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.96 Mil. Therefore, BCAL Diagnostics's EV-to-EBIT for today is -2.78.

The historical rank and industry rank for BCAL Diagnostics's EV-to-EBIT or its related term are showing as below:

ASX:BDX' s EV-to-EBIT Range Over the Past 10 Years
Min: -3.05   Med: 0   Max: 0
Current: -2.78
ASX:BDX's EV-to-EBIT is ranked worse than
100% of 106 companies
in the Medical Diagnostics & Research industry
Industry Median: 20.875 vs ASX:BDX: -2.78

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. BCAL Diagnostics's Enterprise Value for the quarter that ended in Dec. 2024 was A$29.79 Mil. BCAL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.96 Mil. BCAL Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was -26.71%.

BCAL Diagnostics EV-to-EBIT Historical Data

The historical data trend for BCAL Diagnostics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics EV-to-EBIT Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23 Jun24
EV-to-EBIT
-1.71 -1.61 -5.40

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
EV-to-EBIT Get a 7-Day Free Trial - -1.61 - -5.40 -

Competitive Comparison of BCAL Diagnostics's EV-to-EBIT

For the Diagnostics & Research subindustry, BCAL Diagnostics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BCAL Diagnostics's EV-to-EBIT Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, BCAL Diagnostics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BCAL Diagnostics's EV-to-EBIT falls into.


;
;

BCAL Diagnostics EV-to-EBIT Calculation

BCAL Diagnostics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=22.105/-7.956
=-2.78

BCAL Diagnostics's current Enterprise Value is A$22.11 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics  (ASX:BDX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

BCAL Diagnostics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2024 ) =EBIT / Enterprise Value (Q: Dec. 2024 )
=-7.956/29.790896
=-26.71 %

BCAL Diagnostics's Enterprise Value for the quarter that ended in Dec. 2024 was A$29.79 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BCAL Diagnostics's EBIT for the trailing twelve months (TTM) ended in Dec. 2024 was A$-7.96 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » EV-to-EBIT
Comparable Companies
ASX:CTE ASX:RHY ASX:IIQ ASX:IBX ASX:MAP ASX:GSS TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT DGX LH XPAR:BIM ILMN
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
Website
https://www.bcaldiagnostics.com
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.